Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Withdrawn before enrolling · Phase 4 · Has a placebo group

Conditions studied: Opioid-Induced Constipation

In brief

This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous (injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related pain and constipation from taking opioids. The length of participation will be up to 7 weeks.

Key facts

Study ID
NCT00858754
Run by
Bausch Health Americas, Inc.
People needed
0
Starts
2009-03-01
Expected to finish
2009-08-01
Last updated by the study team
2019-11-29

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.